If you’re developing technology that could change outcomes for children with congenital heart disease, EverPulse wants to hear from you. We fund innovators at the stages where it’s hardest to find support.
Early and growth-stage companies developing devices, diagnostics, or monitoring solutions for pediatric cardiac patients. If your technology could improve outcomes for children with CHD, we want to understand what you're building.
University labs and clinical researchers with promising innovations that need funding to move from bench to bedside. We bridge the gap between research and real-world application — the hardest step in the development journey.
Hospitals, health systems, and established medical technology companies looking for pediatric-focused innovation partnerships. We build connections that accelerate timelines and expand impact.
Through grants, pitch competitions, and milestone-based support, we provide innovators with essential early-stage capital without taking equity or royalties.
Donors can recommend that their tax-deductible contributions support specific projects or technologies. While EverPulse retains final discretion to ensure alignment with our mission, we welcome and encourage this kind of purposeful giving.
For promising for-profit ventures, we offer catalytic, impact-first capital through PRIs. These investments aim to drive real-world breakthroughs while allowing any financial return to be reinvested into future pediatric innovation.
Grant applications open in January of 2027. Subscribe to program updates to receive detailed grant proposal information as it becomes available.
Grant applications open in January of 2027. Subscribe to program updates to receive detailed grant proposal information as it becomes available.
Receive funding program updates and announcements.
